GO:0050251 retinol isomerase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050251 (retinol isomerase activity) catalyzes the reversible conversion of all-trans-retinol to 11-cis-retinol, a central step in the visual cycle.
• The best-characterized enzyme carrying this activity is RPE65, which uses all-trans-retinyl ester as a substrate in vivo and is essential for 11-cis-retinal regeneration.
• A distinct retinol isomerase activity that directly converts all-trans-retinol to 11-cis-retinol has been detected in chicken retina, indicating species-specific or enzyme-independent routes.
• RPE65 inhibitors and lipid-metabolism inhibitors can block retinol isomerase activity, linking the visual cycle to pharmacological and metabolic regulation.
• Mutations in RPE65 cause inherited retinal degenerations, including autosomal recessive retinitis pigmentosa and Leber congenital amaurosis, and a dominant p.(E519K) variant causes adult-onset maculopathy.
• Studying GO:0050251 requires a combination of retinoid HPLC, enzymatic assays, CRISPR knockout/knock-in models, and transcriptomic or proteomic readouts.
Description
Retinol isomerase activity (GO:0050251) is a molecular function defined by the catalysis of the reaction all-trans-retinol = 11-cis-retinol. This isomerization is a critical chemical step in the visual cycle, because 11-cis-retinal, the chromophore of rod and cone opsins, must be regenerated continuously to maintain vision. The enzyme most strongly associated with this activity is RPE65, a retinoid isomerase expressed in the retinal pigment epithelium; RPE65 converts all-trans-retinyl esters to 11-cis-retinol in vivo, and its loss causes severe retinal degeneration. In addition to RPE65, a direct all-trans-retinol to 11-cis-retinol isomerase activity has been described in chicken retina, suggesting that multiple enzymatic routes or species-specific mechanisms can contribute to 11-cis-retinoid production. Because defects in retinoid isomerization lead to blinding diseases, GO:0050251 is a high-value target for gene therapy, pharmacological chaperones, and CRISPR-based disease modeling. Researchers studying this term need robust assays and genetically defined cell and animal models to distinguish direct catalytic effects from downstream visual-cycle changes.
retinol isomerase activity At A Glance
| GO ID | GO:0050251 |
|---|---|
| GO term | retinol isomerase activity |
| Ontology | molecular_function |
| Synonym | all-trans-retinol 11-cis-trans-isomerase activity; all-trans-retinol isomerase activity |
| Definition | Catalysis of the reaction: all-trans-retinol = 11-cis-retinol |
| Major function | Isomerization of all-trans-retinol to 11-cis-retinol in the visual cycle |
| Representative enzyme | RPE65 (retinal pigment epithelium-specific 65 kDa protein) |
| Pathway context | Visual cycle / retinoid metabolism |
| Disease relevance | Retinitis pigmentosa, Leber congenital amaurosis, RPE65-associated maculopathy |
What Is GO:0050251?
GO:0050251, retinol isomerase activity, is the catalysis of the reaction all-trans-retinol = 11-cis-retinol. In other words, it is the enzymatic isomerization of the all-trans isomer of retinol (vitamin A alcohol) into its 11-cis configuration. This activity is synonymous with all-trans-retinol 11-cis-trans-isomerase activity and all-trans-retinol isomerase activity. It is a molecular_function term in the Gene Ontology and is distinct from retinoid isomerohydrolase activity that uses retinyl esters as substrates, although RPE65 is the best-characterized enzyme associated with retinol isomerase activity in the visual cycle.
Why Is retinol isomerase activity Important in Cell Biology?
GO:0050251 is important because the isomerization of all-trans-retinol to 11-cis-retinol is a rate-limiting step in the regeneration of the visual chromophore 11-cis-retinal, and its impairment causes retinal degeneration and blindness. The activity is also a pharmacological target: inhibitors of RPE65 and of lipid metabolism can modulate retinol isomerase activity, which has implications for treating visual cycle-associated retinopathies. In addition, the existence of a direct all-trans-retinol to 11-cis-retinol isomerase activity in chicken retina indicates that the enzymatic basis of this GO term is not fully resolved and may involve multiple proteins or species-specific mechanisms. Understanding this activity therefore informs gene therapy, small-molecule drug design, and CRISPR-based disease modeling.
• It produces 11-cis-retinol, the immediate precursor of 11-cis-retinal, the chromophore required for vision.
• Loss of RPE65-associated retinol isomerase activity causes severe inherited retinal dystrophies.
• A dominant RPE65 variant p.(E519K) causes adult-onset maculopathy, showing that gain-of-function or dominant-negative mechanisms can also disrupt this activity.
• Pharmacological inhibition of RPE65 is being explored for visual cycle-associated retinopathies.
• Inhibitors of lipid metabolism can inhibit RPE65 retinol isomerase activity, linking this GO term to cellular lipid handling.
• A direct all-trans-retinol to 11-cis-retinol isomerase activity in chicken retina suggests alternative enzymatic routes.
• Retinol isomerase activity is a biomarker and target in preclinical retinopathy models and drug repurposing studies.
• CRISPR knockout and knock-in models of RPE65 and related genes enable causal testing of this activity.
Mechanism, Genes and Research Methods
Substrate recognition and binding
In simple terms: The enzyme must grab the correct form of vitamin A before it can change its shape.
Retinol isomerase activity acts on all-trans-retinol, converting it to 11-cis-retinol. In the visual cycle, RPE65 is the principal enzyme associated with this activity, and it operates within the retinal pigment epithelium where retinoids are stored and processed. The enzyme must bind the all-trans isomer and orient it for isomerization; the reaction is reversible in principle, but in vivo the visual cycle pulls the equilibrium toward 11-cis-retinol production. A distinct direct isomerase activity that converts all-trans-retinol to 11-cis-retinol has been detected in chicken retina, indicating that substrate handling may differ between species or enzyme complexes.
Catalytic isomerization step
In simple terms: The enzyme twists the molecule so that the double bond switches from trans to cis.
The catalytic event of GO:0050251 is the isomerization of all-trans-retinol to 11-cis-retinol. RPE65 is the best-characterized protein carrying this activity, and its role in the visual cycle is essential for regenerating 11-cis-retinal. The reaction is chemically demanding because it requires breaking and reforming a double bond geometry without adding or removing atoms. Inhibitors of lipid metabolism can inhibit RPE65 retinol isomerase activity, suggesting that the catalytic environment or substrate presentation depends on lipid handling. Rationally designed short-acting RPE65 inhibitors further demonstrate that the catalytic step can be blocked pharmacologically.
Product release and visual cycle coupling
In simple terms: After the shape change, the product is handed off to the next step that makes the visual pigment.
Once 11-cis-retinol is produced by retinol isomerase activity, it is further oxidized to 11-cis-retinal, which combines with opsin to form the visual pigment. This coupling means that defects in GO:0050251 reduce the available chromophore and impair photoreceptor function. In RPE65-associated disease, the failure to produce 11-cis-retinol leads to accumulation of all-trans-retinyl esters and progressive retinal degeneration. The direct all-trans-retinol to 11-cis-retinol activity in chicken retina may feed into the same pool of 11-cis-retinoids, but its physiological role remains to be fully defined.
Enzyme structure and membrane association
In simple terms: The enzyme sits in a membrane and needs a specific environment to work.
RPE65 is a retinal pigment epithelium-specific 65 kDa protein that carries retinol isomerase activity and is associated with the visual cycle. Its activity is sensitive to inhibitors of lipid metabolism, indicating that membrane lipids and retinoid storage forms influence catalysis. The existence of a direct retinol isomerase activity in chicken retina suggests that additional proteins or complexes may carry this function in some species. Structural and biochemical studies of RPE65 have informed the design of short-acting inhibitors that modulate its activity.
Regulation by retinoid and lipid status
In simple terms: How much vitamin A and fat is around can change how fast the enzyme works.
Retinol isomerase activity is regulated by the availability of all-trans-retinol and by lipid metabolic state, as shown by inhibition of RPE65 retinol isomerase activity by inhibitors of lipid metabolism. Pharmacological inhibitors can acutely reduce the activity, which is being explored for visual cycle-associated retinopathies. In disease, mutations such as RPE65 p.(E519K) can alter activity in a dominant manner, leading to adult-onset maculopathy. These findings indicate that GO:0050251 is not a fixed constant but a regulated node responsive to metabolic and genetic inputs.
Key Genes Involved in GO:0050251 retinol isomerase activity
The following genes and proteins are directly or indirectly implicated in retinol isomerase activity (GO:0050251) and its visual cycle context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RPE65 | Retinoid isomerase in the visual cycle; carries retinol isomerase activity | Central enzyme for GO:0050251; mutations cause retinal degeneration |
| LRAT | Lecithin retinol acyltransferase; esterifies all-trans-retinol | Provides substrate for RPE65-dependent isomerization |
| RLBP1 | Cellular retinaldehyde-binding protein; binds 11-cis-retinal | Downstream carrier of 11-cis-retinoids |
| RDH5 | 11-cis-retinol dehydrogenase | Converts 11-cis-retinol to 11-cis-retinal |
| RDH11 | Retinol dehydrogenase | Contributes to retinoid oxidation in the visual cycle |
| ABCA4 | Retinoid transporter in photoreceptors | Mutations cause Stargardt disease and alter retinoid flux |
| RHO | Rhodopsin; binds 11-cis-retinal | Loss causes retinitis pigmentosa; depends on 11-cis-retinal supply |
| PDE6A | Photoreceptor phosphodiesterase | Retinal degeneration gene used in preclinical models |
| PDE6B | Photoreceptor phosphodiesterase | Retinal degeneration gene used in preclinical models |
| CNGA1 | Rod cyclic nucleotide-gated channel | Retinitis pigmentosa gene |
| CNGB1 | Rod cyclic nucleotide-gated channel | Retinitis pigmentosa gene |
| NR2E3 | Photoreceptor transcription factor | Retinal degeneration gene |
| CRX | Photoreceptor transcription factor | Retinitis pigmentosa gene |
| NRL | Photoreceptor transcription factor | Retinitis pigmentosa gene |
| IMPDH1 | Inosine monophosphate dehydrogenase | Retinitis pigmentosa gene |
| PRPF31 | Pre-mRNA splicing factor | Retinitis pigmentosa gene |
| USH2A | Usher syndrome protein | Retinitis pigmentosa gene |
How Is retinol isomerase activity Regulated?
Retinol isomerase activity is regulated at multiple levels. At the metabolic level, inhibitors of lipid metabolism can inhibit RPE65 retinol isomerase activity, indicating that lipid handling and retinoid ester pools influence the reaction. Pharmacological regulation is also possible: rationally designed short-acting RPE65 inhibitors can acutely modulate the activity, which is being explored for visual cycle-associated retinopathies. At the genetic level, mutations such as RPE65 p.(E519K) can cause a dominant adult-onset maculopathy, showing that altered protein function can dysregulate the activity. In disease models, combination treatments based on drug repurposing can modify retinopathy progression, indirectly reflecting changes in visual cycle flux. Together, these findings indicate that GO:0050251 is a regulated node responsive to metabolic, pharmacological, and genetic inputs.
retinol isomerase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RPE65 | Autosomal recessive retinitis pigmentosa; Leber congenital amaurosis; adult-onset maculopathy (p.E519K) | RPE65 knockout and p.(E519K) knock-in cell and mouse models |
| LRAT | Retinoid metabolism defects; retinal degeneration | LRAT knockout models to study substrate supply for retinol isomerase |
| RDH5 | Fundus albipunctatus; delayed dark adaptation | RDH5 knockout models to study 11-cis-retinol handling |
| ABCA4 | Stargardt disease; altered retinoid flux | ABCA4 knockout models to study visual cycle load |
| PDE6A/PDE6B | Retinitis pigmentosa; preclinical retinopathy models | PDE6A/PDE6B mutant models for drug repurposing studies |
RPE65-associated inherited retinal degeneration
Mutations in RPE65, the principal enzyme carrying retinol isomerase activity, cause autosomal recessive retinitis pigmentosa and Leber congenital amaurosis, both of which involve progressive loss of photoreceptors due to failure of 11-cis-retinal regeneration. A dominant RPE65 variant p.(E519K) has been reported to cause a novel adult-onset maculopathy in 83 affected individuals, expanding the phenotypic spectrum associated with altered retinol isomerase activity. These disorders highlight the critical dependence of vision on GO:0050251.
Pharmacological modulation of the visual cycle
Because retinol isomerase activity is rate-limiting for chromophore regeneration, inhibitors of RPE65 are being developed for visual cycle-associated retinopathies. Inhibitors of lipid metabolism can also inhibit RPE65 retinol isomerase activity, linking the visual cycle to cellular lipid handling and suggesting additional pharmacological entry points. Short-acting RPE65 inhibitors have been rationally designed to modulate the activity with potentially improved safety profiles.
Preclinical retinopathy models and drug repurposing
Combination treatments based on drug repurposing have shown mutation-agnostic efficacy in preclinical retinopathy models, demonstrating that visual cycle flux and retinol isomerase activity can be modified therapeutically. These models are valuable for testing whether restoring or modulating GO:0050251 can slow degeneration across different genetic causes.
From retinol isomerase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of RPE65 abolish retinol isomerase activity? | RPE65 knockout cell line and mouse model |
| Does the p.(E519K) variant alter activity dominantly? | RPE65 p.(E519K) knock-in cell and animal model |
| Can pharmacological inhibitors block retinol isomerase activity? | Wild-type RPE65-expressing cells treated with RPE65 inhibitors |
| Does lipid metabolism inhibition affect retinol isomerase activity? | Cells treated with lipid metabolism inhibitors and assayed for retinoid isomerization |
| Is there a direct all-trans-retinol to 11-cis-retinol activity in non-mammalian retina? | Chicken retina preparations and retinal pigment epithelium assays |
| Can drug repurposing slow retinopathy progression? | Preclinical retinopathy models with combination treatments |
How to Study the retinol isomerase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Retinoid HPLC | Levels of all-trans-retinol and 11-cis-retinol | Direct assay of retinol isomerase activity |
| Enzyme activity assay with inhibitors | Sensitivity of isomerization to inhibitors | Testing lipid metabolism and RPE65 inhibitors |
| CRISPR knockout | Requirement of a gene for the activity | RPE65 and related gene knockouts |
| CRISPR knock-in | Effect of disease variants on activity | RPE65 p.(E519K) modeling |
| RNA-seq | Transcriptional changes after perturbation | Identifying downstream networks |
| Proteomics | Protein abundance and interactions | Characterizing enzyme complexes |
| Electroretinography | Retinal function in vivo | Preclinical retinopathy models |
| Retinoid profiling in animal models | Visual cycle flux in vivo | Drug repurposing studies |
Retinoid HPLC and enzymatic assays
Direct measurement of retinol isomerase activity requires separation and quantification of all-trans-retinol and 11-cis-retinol, typically by high-performance liquid chromatography (HPLC). These assays can be applied to retinal pigment epithelium preparations, cell lysates, or recombinant enzyme systems to test whether a candidate protein carries GO:0050251. Inhibitor studies using lipid metabolism inhibitors or RPE65 inhibitors can be incorporated to probe catalytic requirements.
CRISPR knockout and knock-in models
CRISPR-Cas9 knockout of RPE65 or related genes provides a clean genetic test of whether a gene is required for retinol isomerase activity. Knock-in of disease-associated variants such as RPE65 p.(E519K) allows assessment of dominant or gain-of-function effects on the activity. These models can be combined with retinoid HPLC to link genotype to enzymatic output.
Transcriptomic and proteomic profiling
RNA-seq and proteomics can identify genes and proteins whose expression changes when retinol isomerase activity is perturbed, revealing downstream visual cycle and lipid metabolic networks. Such profiling is useful for generating hypotheses about regulators of GO:0050251 and for validating drug repurposing candidates.
Preclinical retinopathy models and functional readouts
Animal models of retinal degeneration, including PDE6A and PDE6B mutants, can be used to test whether modulating retinol isomerase activity affects photoreceptor survival and function. Combination treatments based on drug repurposing have shown mutation-agnostic efficacy in such models, supporting the use of functional readouts such as electroretinography and retinoid profiling.
How CRISPR Can Be Used to Study GO:0050251 retinol isomerase activity
Knockout
CRISPR knockout of RPE65 or candidate genes is used to test whether a specific protein is required for retinol isomerase activity. Loss-of-function models can be assayed by retinoid HPLC to confirm loss of 11-cis-retinol production. Such knockouts also provide clean backgrounds for rescue experiments and for testing pharmacological inhibitors.
Point Mutation
Point mutations identified in patients, such as RPE65 p.(E519K), can be introduced by CRISPR to model dominant or subtle effects on retinol isomerase activity. These models help distinguish loss-of-function from dominant-negative or gain-of-function mechanisms. They are also useful for testing allele-specific therapeutics.
Knock-in
Knock-in of reporter tags or disease variants allows tracking of enzyme localization and activity in live cells. Tagged knock-in models can be used to purify the enzyme complex and identify interacting proteins. Disease-variant knock-ins support preclinical evaluation of visual cycle modulators.
Overexpression
Overexpression of RPE65 or candidate isomerases can be used to boost retinol isomerase activity and test whether increased flux is protective or toxic in retinal models. Overexpression systems also facilitate biochemical purification and inhibitor screening. In combination with knockout backgrounds, overexpression can establish sufficiency of a gene for the activity.
How EDITGENE Supports retinol isomerase activity Research
Researchers studying retinol isomerase activity-related genes often need to determine whether a candidate gene is causally involved in all-trans-retinol to 11-cis-retinol conversion, whether a disease variant alters catalytic function, and how the activity responds to pharmacological or metabolic perturbation. Answering these questions requires genetically defined cell and animal models, quantitative retinoid assays, and unbiased profiling of downstream networks.
Contact EDITGENE today to design your custom CRISPR model for retinol isomerase activity research.
Frequently Asked Questions About retinol isomerase activity
What is retinol isomerase activity?
Retinol isomerase activity (GO:0050251) is the catalysis of the reaction all-trans-retinol = 11-cis-retinol, a key step in the visual cycle.
What genes are involved in retinol isomerase activity?
RPE65 is the principal gene associated with retinol isomerase activity; related visual cycle genes include LRAT, RLBP1, RDH5, and RDH11.
What is the GO ID for retinol isomerase activity?
The Gene Ontology ID for retinol isomerase activity is GO:0050251.
Which enzyme catalyzes all-trans-retinol to 11-cis-retinol?
RPE65 is the best-characterized enzyme carrying retinol isomerase activity, and a direct activity has also been detected in chicken retina.
What diseases are linked to retinol isomerase activity?
Mutations in RPE65 cause retinitis pigmentosa, Leber congenital amaurosis, and an adult-onset maculopathy, all linked to defective 11-cis-retinal regeneration.
Can retinol isomerase activity be inhibited?
Yes, RPE65 inhibitors and inhibitors of lipid metabolism can inhibit retinol isomerase activity.
How do you measure retinol isomerase activity?
Retinol isomerase activity is typically measured by HPLC quantification of all-trans-retinol and 11-cis-retinol in enzymatic assays.
Is there a direct all-trans-retinol to 11-cis-retinol isomerase in chicken retina?
Yes, chicken retinas contain a retinoid isomerase activity that catalyzes the direct conversion of all-trans-retinol to 11-cis-retinol.
What is the RPE65 p.(E519K) variant?
RPE65 p.(E519K) is a dominant variant that causes a novel adult-onset maculopathy in affected individuals.
How can CRISPR help study retinol isomerase activity?
CRISPR knockout, knock-in, and overexpression models allow causal testing of genes and variants that affect retinol isomerase activity.
Conclusion
Retinol isomerase activity (GO:0050251) is a central enzymatic step in the visual cycle, converting all-trans-retinol to 11-cis-retinol and supporting the regeneration of 11-cis-retinal required for vision. RPE65 is the principal enzyme associated with this activity, and its dysfunction causes inherited retinal degenerations, including retinitis pigmentosa, Leber congenital amaurosis, and an adult-onset maculopathy linked to the p.(E519K) variant. The detection of a direct all-trans-retinol to 11-cis-retinol activity in chicken retina indicates that the enzymatic basis of this GO term may be broader than a single protein. Pharmacological modulation of retinol isomerase activity, including RPE65 inhibitors and lipid metabolism inhibitors, is an active area of therapeutic development. CRISPR-based knockout, knock-in, and overexpression models combined with retinoid HPLC and omics profiling provide a rigorous path to dissect the mechanisms and disease relevance of GO:0050251.
References
- 1. Adam MP et al.. 1993. Nonsyndromic Retinitis Pigmentosa Overview.. PMID: 20301590
- 2. Leinonen H et al.. 2024. A combination treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy models.. Nat Commun 15(1):5943 PMID: 39009597
- 3. Eroglu A et al.. 2016. Inhibition of RPE65 Retinol Isomerase Activity by Inhibitors of Lipid Metabolism.. J Biol Chem 291(10):4966-73 PMID: 26719343
- 5. Saari JC. 2016. Vitamin A and Vision.. Subcell Biochem 81:231-259 PMID: 27830507
- 6. Mata NL et al.. 2005. Chicken retinas contain a retinoid isomerase activity that catalyzes the direct conversion of all-trans-retinol to 11-cis-retinol.. Biochemistry 44(35):11715-21 PMID: 16128572
- 7. Bassetto M et al.. 2025. Rationally Designed, Short-Acting RPE65 Inhibitors for Visual Cycle-Associated Retinopathies.. J Med Chem 68(16):17638-17652 PMID: 40764714
- 8. Van Vooren E et al.. 2025. RPE65 Variant p.(E519K) Causes a Novel Dominant Adult-Onset Maculopathy in 83 Affected Individuals.. Invest Ophthalmol Vis Sci 66(12):53 PMID: 40985799
